Biotechnology company developing adaptive and controllable cell therapies for cancer treatment.
Arcellx, Inc., headquartered in Gaithersburg, Maryland, is a dynamic clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for patients grappling with cancer and other challenging diseases. At the forefront of its portfolio is CART-ddBCMA, the company's lead dual-targeting chimeric antigen receptor (ddCAR) T cell product candidate currently undergoing Phase 1 clinical trials for relapsed or refractory (r/r) multiple myeloma (MM). This innovative therapy aims to enhance treatment outcomes by targeting specific cancer markers.
In addition to CART-ddBCMA, Arcellx is pioneering ACLX-001, a groundbreaking combination therapy comprising ARC-T cells and bi-valent SparX proteins that selectively target BCMA, further advancing treatment options for r/r MM. The company is also actively developing ACLX-002 and ACLX-003, focusing on novel immunotherapeutic approaches for r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), along with other promising programs targeting solid tumors.
Arcellx's strategic partnership with Kite, a Gilead company, exemplifies its collaborative approach to innovation and market expansion. This alliance is geared toward co-developing and co-commercializing CART-ddBCMA, underscoring Arcellx's commitment to leveraging synergies within the biopharmaceutical industry to accelerate the delivery of transformative therapies.
Founded in 2014 as Encarta Therapeutics, Inc., and rebranded as Arcellx, Inc. in January 2016, the company continues to push the boundaries of scientific discovery in immunotherapy. With a robust pipeline and a focus on precision medicine, Arcellx is poised to make significant strides in improving treatment options and outcomes for patients confronting complex oncological and hematological conditions.